Clinical Decision Support Clinical Trial
Official title:
Showing Health Information Value in a Community Network
Verified date | December 2012 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The purpose of this study is to determine the value of shared health information on care quality and costs when this information is used to notify care providers about concerning health events for patients cared for by a community-based network of providers.
Status | Completed |
Enrollment | 20108 |
Est. completion date | August 2008 |
Est. primary completion date | July 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Enrollment in the Community Care of North Carolina Medicaid program in Durham County North Carolina Exclusion Criteria: |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Duke University Medical Center | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Duke University |
United States,
Eisenstein EL, Anstrom KJ, Macri JM, Crosslin DR, Johnson FS, Kawamoto K, Lobach DF. Assessing the potential economic value of health information technology interventions in a community-based health network. AMIA Annu Symp Proc. 2005:221-5. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Emergency department utilization rates and hospitalization rates | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | ED encounter rates for low severity conditions | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | ED encounter rates for asthma | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | ED encounter rates for diabetes | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | Hospitalization rates | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | Hospitalization rates for asthma (also PQI) | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | Hospitalization rates for diabetes (also PQI) | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | Glycemic control (hemoglobin A1c) | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | Medication contraindications | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | HEDIS - Preventive services | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | HEDIS - # WCC visits | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | AHRQ Prevention Quality Indicators | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | HEDIS - Asthma and diabetes | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | # of messages triggered for health risks | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | # of messages triggered for barriers to care | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | Missed appointment rates | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | Primary care appointment rates | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | F/U rates post-partum | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | Patient satisfaction instruments (CHAPS) | at 6 to 9 months after the intervention has been introduced and then at 3 to 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | EuroQoL | at 6 to 9 months after the intervention has been introduced and then at 3 to 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | Provider opinion surveys | At conclusion of study | No | |
Secondary | Costs of ED utilization for all causes | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | Costs of ED use for asthma | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | Costs of ED use for diabetes | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | Costs of ED use for low severity visits | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | Hospitalization costs for all causes | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | Hospitalization costs for asthma | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | Hospitalization costs for diabetes | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | Reimbursement for labs+other ancillary services | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | Primary care reimbursement | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No | |
Secondary | ED rates for recurrent ED encounters | at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03658642 -
Clinical Decision Support to Implement ED-initiated Buprenorphine for OUD
|
N/A | |
Withdrawn |
NCT02365792 -
Professional Development in Emergency Medical Services
|
N/A | |
Completed |
NCT05034718 -
Implementation of the Pittsburgh Infant Brain Injury Score
|
N/A | |
Not yet recruiting |
NCT06456658 -
Statin Reminders for Improving Prescribing in Primary Care
|
N/A | |
Completed |
NCT03415425 -
Optimizing the Influenza Clinical Decision Support Tool
|
N/A | |
Recruiting |
NCT03989167 -
Clinical Decision Support for Familial Hypercholesterolemia
|
N/A |